Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA)

Preetesh Jain; Sergej Konoplev; Ohad Benjamini; Jorge Romagura; Jan A. Burger

doi:10.5045/br.2018.53.2.169

Quick links

Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2018; 53(2):

Published online June 25, 2018

https://doi.org/10.5045/br.2018.53.2.169

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As₂O₃) and all-trans retinoic acid (ATRA)

Preetesh Jain¹, Sergej Konoplev², Ohad Benjamini¹, Jorge Romagura³, and Jan A. Burger^1*

Author Info. +

¹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

²Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

³Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Correspondence to : Jan A. Burger. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. jaburger@mdanderson.org

Received: November 4, 2017; Revised: December 7, 2017; Accepted: December 27, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Letter to the Editor

Blood Res 2018; 53(2): 169-172

Published online June 25, 2018 https://doi.org/10.5045/br.2018.53.2.169

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As₂O₃) and all-trans retinoic acid (ATRA)

Preetesh Jain¹, Sergej Konoplev², Ohad Benjamini¹, Jorge Romagura³, and Jan A. Burger^1*

¹Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

²Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

³Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Correspondence to:Jan A. Burger. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. jaburger@mdanderson.org

Received: November 4, 2017; Revised: December 7, 2017; Accepted: December 27, 2017

Fig 1.

Download

Figure 1.Mammogram showing extramedullary relapse of follicular lymphoma in the breast (A). Hematoxylin and eosinophil (H&E) staining of breast biopsy showing follicular lymphoma (B, ×100).

Blood Research 2018; 53: 169-172https://doi.org/10.5045/br.2018.53.2.169

Fig 2.

Download

Figure 2.Positron emission tomography scans showing response to all-trans retinoic acid (ATRA) with arsenic trioxide therapy: left axillary lymph node mass before (A) and after therapy (B), hematoxylin and eosinophil (H&E) staining of axillary lymph node showing follicular lymphoma (C, ×100), immunohistochemistry showing positive Bcl2 staining (D, ×100), bone marrow showing acute promyelocytic leukemia cells with multiple auer rods (E, ×1,000).

Blood Research 2018; 53: 169-172https://doi.org/10.5045/br.2018.53.2.169